News & Events

Blog

  • April 25, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPh, MS

    Photo: Dan Saelinger/Trunk Archive, accessed from the Consumer Reports Article published on line on Apri 5, 2018. The feature article written by Lisa Gill and published on April 5th 2018 by Consumer Reportstitled “How to Pay Less for Your Meds” is one of the best patient-focused articles on drug prices written in the past year.  […]

  • April 18, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPh, MS

    The opioid epidemic could have been prevented if pharmacists had prescriptive and provider rights. I would also argue that this would solve the enormous problem we have in hand today.  Crazy? I say not at all.  Let’s consider. One of the problems is over prescribing by those who CAN prescribe: doctors, nurse practitioners and, in […]

  • April 11, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPh, MS; Contributor: Martha Morton

    Recently there has been a buzz over social media and the news about the rising prices of prescription drugs. The blame has been mostly placed on the drug manufacturers. The spikes in medication prices are notable, for it has been documented that prices have increased, what feels like overnight, by the thousands per pill. I […]

  • April 4, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken

    %Rx ≠ $Rx Prescription drugs prices continue to go up every year. Is it the disaster they say it is? Perhaps not. Why? CNN recently published an article about soaring drug prices and used only percentages to prove its point that there is a real problem when it comes to the cost of prescription drugs […]

  • March 29, 2018
    Posted by: Gerald (Pharmacist Jerry) Finken; Meghan P. Robbins, contributor

    Disruption is coming to the healthcare industry.  In recent months multiple announcements have been made about enterprises joining together. Between Amazon dabbling in the pharmacy industry and CVS and Aetna announcing a potential merger, disruption is here. But it doesn’t stop there. Now Amazon, Berkshire Hathaway and JPMorgan have a plan to overhaul health insurance.  […]

  • March 14, 2018
    Posted by: Gerald “Pharmacist Jerry” Finken, RPH, MS. Contributor: Meghan P. Robbins

    Several articles have been published about CVS buying the insurance company Aetna, including the Wall Street Journal.  The article claimed there was a hidden reason behind this venture. That hidden reason was summed up in one word:  Amazon.  In my opinion, this is correct. Two major healthcare companies are joining forces to likely compete against […]

  • March 7, 2017
    Posted by: Theresa Matkovits, Ph.D., Senior Vice President, Head of Drug Development, ContraVir Pharmaceuticals

    The high failure rate of clinical trials has significant impact on providing potential curative treatments to patients in need. It is with this goal in mind that innovators struggle in designing clinical programs that can bring life-changing treatments to market. Drug development remains a high cost and risky undertaking, given the high failure rate if […]

  • February 28, 2017
    Posted by: Nicki Norris, Chief Executive Officer, Symphony Clinical Research

    In the US, pharmaceutical and biotechnology companies sponsor the majority (75%) of clinical trials. In total, these companies spent approximately $40 billion on clinical research in 2014. [1] Clinical trials such as these are the first point of interaction between a patient and a sponsor company. In spite of this, clinical teams frequently overlook this […]

  • February 21, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is the third and last part of a 3-part series on strategic considerations for patient engagement, market access and promotion for medical devices and procedures. In this blog, we’ll discuss the important factors from the Company’s perspective. We’ll look to discuss what the mission critical factors are for device success, after you’ve completed all […]

  • February 7, 2017
    Posted by: Joe Martinez, RPh, PDE, PPC

    This is the second part of a 3-part series on strategic considerations for patient engagement, market access and promotion for medical devices and procedures. In this blog, we’ll discuss the important factors from the payer’s perspective that many times are overlooked and not given their full due by well-meaning corporate teams. As an early disclaimer, […]

  • Case Study
    A Biopharmaceutical Company Sponsoring a Phase II Clinical Trial in the U.S.
    read more...
  • Latest News
    Center Point Clinical Services Names Gerald E. Finken New CEO
    March 15, 2018
    read more...
  • Need More Information?